Bo Chen
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 5%
- Circular RNAs in diseases
- Epigenetics and DNA Methylation
- Medicinal Plants and Bioactive Compounds
- RNA modifications and cancer
Papers in
-
- MicroRNA in disease regulation 8
- Breast Cancer Treatment Studies 6
-
- Epigenetics and DNA Methylation 11
- Ubiquitin and proteasome pathways 6
- Co-authors
- Hailin Tang (4 shared papers)Xiaoming Xie (4 shared papers)Anxian Lu (2 shared papers)Xiaojia Huang (3 shared papers)Cong Li (1 shared paper)Weidong Wei (2 shared papers)Danian Dai (2 shared papers)Li Zhang (1 shared paper)
- Journals
- Scientific Reports (6 papers)Frontiers in Oncology (5 papers)Gene (3 papers)Frontiers in Pharmacology (3 papers)Biochemical and Biophysical Research Communications (3 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Bo Chen
160 papers receiving 3.6k citations
Peers
Comparison fields: 5 of 150
- Cancer Research 598
- Molecular Biology 1.7k
- Pharmacology 115
- Neurology 188
- Health, Toxicology and Mutagenesis 177
Countries citing papers authored by Bo Chen
This map shows the geographic impact of Bo Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Chen more than expected).
Fields of papers citing papers by Bo Chen
This network shows the impact of papers produced by Bo Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Chen. The network helps show where Bo Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Bo Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 167 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 240 | |
| 2 | 2018 | 222 | |
| 3 | 2011 | 153 | |
| 4 | 2011 | 147 | |
| 5 | 2018 | 131 | |
| 6 | 2016 | 117 | |
| 7 | 2012 | 91 | |
| 8 | 2020 | 84 | |
| 9 | 2016 | 73 | |
| 10 | 2011 | 67 | |
| 11 | 2009 | 64 | |
| 12 | 2018 | 61 | |
| 13 | 2022 | 61 | |
| 14 | 2012 | 61 | |
| 15 | 2011 | 60 | |
| 16 | 2014 | 59 | |
| 17 | 2019 | 59 | |
| 18 | 2022 | 57 | |
| 19 | 2015 | 57 | |
| 20 | 2018 | 56 |
About Bo Chen
Bo Chen is a scholar working on Cancer Research, Molecular Biology, Neurology, Pulmonary and Respiratory Medicine and Immunology, having authored 167 papers that have together received 3.6k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (11 papers), Ferroptosis and cancer prognosis (9 papers), Traumatic Brain Injury and Neurovascular Disturbances (8 papers), MicroRNA in disease regulation (8 papers), Autophagy in Disease and Therapy (6 papers), Ubiquitin and proteasome pathways (6 papers), Breast Cancer Treatment Studies (6 papers) and Endoplasmic Reticulum Stress and Disease (5 papers). The work is most often cited by research in Cancer Research (598 citations), Molecular Biology (1.7k citations), Pharmacology (115 citations), Neurology (188 citations) and Health, Toxicology and Mutagenesis (177 citations). Bo Chen has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Hailin Tang, Xiaoming Xie, Anxian Lu, Xiaojia Huang, Cong Li, Weidong Wei, Danian Dai, Li Zhang, Guo-xian Cao and Yang Sun. Their work appears in journals such as Scientific Reports, Frontiers in Oncology, Gene, Frontiers in Pharmacology and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.